Drug Channels

JULY 28, 2022

When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2021. Consistent with our previous analyses, rebates and discounts reduced the selling prices of brand-name drugs to less than half of their list prices. healthcare expenditures. healthcare expenditures.

Drug Pricing 98

Drug Pricing Pharmaceutical Manufacturing 98

STAT

JULY 22, 2024

The findings are likely to intensify scrutiny of the controversial role played by PBMs in the opaque pharmaceutical pricing system. Notably, nearly half of the overcharges stemmed from drug rebates that Express Scripts negotiated with pharmaceutical companies.

Pharmaceutical Companies 363

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 363

STAT

MAY 6, 2024

A battle between the Arkansas Insurance Department and AstraZeneca is heating up with an August hearing scheduled to consider penalties against the company, which filed a lawsuit against the state earlier this year over a law known as the 340B Drug Pricing Nondiscrimination Act, The Arkansas Democrat-Gazette reports.

Drug Pricing 266

Drug Pricing 266

Drug Channels

SEPTEMBER 13, 2021

Informa Connect’s Drug Pricing Transparency Congress. Delivered as a Hybrid Event In-Person: November 9-10 | Philadelphia, PA Virtual: November 16-17 www.informaconnect.com/drug-pricing-transparency. Drug Channels, or any of its employees. Copyright © 2006-2021 Pembroke Consulting, Inc.

Drug Pricing 75

Drug Pricing 75

Drug Channels

SEPTEMBER 28, 2021

Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the Drug Channels patch: Fresh insights about hospitals’ specialty drug profits SSR Update: Drug prices keep dropping My $0.02 Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Drug Pricing 81

Drug Pricing Hospitals Biosimilars 81

Drug Channels

SEPTEMBER 24, 2023

Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. billion (+22.3%) higher than its 2021 counterpart. The difference between list prices and discounted 340B purchases also grew, to $52.3 The difference between list prices and discounted 340B purchases also grew, to $52.3

Drug Pricing 96

Drug Pricing Hospitals 96

Drug Channels

MARCH 8, 2022

It’s the 13th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system. prescription dispensing revenues for calendar year 2021. prescription dispensing revenues reached a record $501 billion in 2021.

Drug Pricing 98

Drug Pricing 98

Drug Channels

AUGUST 15, 2022

Here’s a summer surprise for fans of the 340B Drug Pricing Program: Drug Channels has just obtained the 2021 figures from the Health Resources and Services Administration (HRSA)! For 2021, discounted purchases under the 340B program reached a record $43.9 The data tell a familiar story. billion —an astonishing $5.9

Hospitals 98

Hospitals Drug Pricing 98

Drug Channels

DECEMBER 15, 2023

Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. billion (+22.3%) higher than its 2021 counterpart. The difference between list prices and discounted 340B purchases also grew, to $52.3 The difference between list prices and discounted 340B purchases also grew, to $52.3

Drug Pricing 98

Drug Pricing Hospitals 98

Drug Channels

JULY 26, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. More than $122 billion in "savings" (offsets) from the current drug pricing reconciliation legislation comes from blocking rebate reform—which never even happened.

Drug Pricing 94

Drug Pricing 94

STAT

APRIL 10, 2024

From 2012 to 2021, Regeneron’s credit card fee reimbursements for Eylea purchases exceeded $250 million to just one of its several distributors. Continue to STAT+ to read the full story…

Drug Pricing 328

Drug Pricing 328

Drug Channels

DECEMBER 16, 2022

Fortunately, my 2022 FOIA efforts (described below) extracted purchases by 340B covered entity type for 2015 through 2021. Here’s a summer surprise for fans of the 340B Drug Pricing Program: Drug Channels has just obtained the 2021 figures from the Health Resources and Services Administration (HRSA)!

Hospitals 97

Hospitals Drug Pricing 97

STAT

JULY 24, 2023

AbbVie, Teva Pharmaceutical, and AstraZeneca left over a span of five months following the passage of the drug-pricing reform law pushed by Democrats last year. Drug companies are systematically funding grassroots patient groups that lobby the U.K. Financial interests were often not clearly disclosed in NICE documents.

Drug Pricing 242

Drug Pricing Documentation 242

Drug Channels

DECEMBER 8, 2020

When Americans complains about “drug prices,” most are actually complaining about the share of costs they pay—and how those costs are computed. drug channel. Today, I review four crucial issues that the new Congress could tackle to address affordability, patients' out-of-pocket obligations, and prescription prices.

Drug Pricing 52

Drug Pricing 52

STAT

MARCH 20, 2024

At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., Continue to STAT+ to read the full story…

Drug Pricing 363

Drug Pricing 363

Drug Channels

MARCH 25, 2021

This week, I’m rerunning some popular posts while I prepare for tomorrow's live video webinar: Drug Channels Quarterly Update: Patients, Payers, and PBMs. When Americans complain about “drug prices,” most are actually complaining about the share of costs they pay—and how those costs are computed. drug channel.

Drug Pricing 52

Drug Pricing 52

STAT

MAY 4, 2023

Between 2012 and 2021, 14% of roughly 19,000 patent applications did not disclose financial support from the NIH or did not do so as required by federal law. And a new analysis finds a key reason may be most institutions and researchers that receive NIH support fail to fully or correctly disclose this information when applying for patents.

Drug Development 260

Drug Development Drug Pricing 260

STAT

OCTOBER 18, 2023

… Investors in biopharma companies, who lobbied vigorously — but unsuccessfully — against allowing Medicare to negotiate drug prices, are trying a new tactic to preserve their profits , The Boston Globe tells us.  Between 2017 and 2021, annual new HIV infections fell by 12%.

Drug Pricing 276

Drug Pricing 276

Drug Channels

MARCH 23, 2021

Click here to see the original post and comments from January 2021. It was another year of unexpected drug price developments. In 2020, brand-name drug net prices dropped for the third consecutive year. Meanwhile, brand-name drug list prices grew at their slowest rate in at least 20 years.

Drug Pricing 52

Drug Pricing 52

STAT

DECEMBER 29, 2022

The downfall of Aduhelm, the first new treatment for Alzheimer’s disease in two decades, is largely the story of a drug company choosing to maximize its potential profits at the expense of patients and taxpayers, according to a congressional investigation that cites thousands of pages of internal Biogen documents.

Documentation 246

Documentation Drug Pricing 246

Drug Channels

MARCH 21, 2022

Time for Drug Channels Institute’s annual update on the gross-to-net bubble —the ever-growing dollar gap between sales at brand-name drugs' list prices and their sales at net prices after rebates and other reductions. drug prices. d/b/a Drug Channels Institute.

Drug Pricing 75

Drug Pricing 75

Drug Channels

NOVEMBER 23, 2021

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter. d/b/a Drug Channels Institute.

Specialty Pharmacies 75

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 75

Drug Channels

NOVEMBER 23, 2021

Please join me for my upcoming live video webinar, Drug Channels Outlook 2022 , on December 17, 2021, from 12:00 p.m. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Happy Thanksgiving, everyone!

Specialty Pharmacies 75

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 75

Drug Channels

JANUARY 5, 2021

It was another year of unexpected drug price developments. In 2020, brand-name drug net prices dropped for the third consecutive year. Meanwhile, brand-name drug list prices grew at their slowest rate in at least 20 years. I also review the factors behind declining brand-name drug prices.

Drug Pricing 52

Drug Pricing 52

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Drug Pricing 75

Drug Pricing Biosimilars Hospitals 75

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Drug Pricing 74

Drug Pricing Biosimilars Hospitals 74

Drug Channels

MARCH 5, 2021

Edward discusses the impact of providing access to drug price transparency and affordability programs to healthcare providers and patients at the point of care. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. To learn more about AssistRx’s solutions, visit AssistRx.com.

Drug Pricing 52

Drug Pricing 52

Drug Channels

NOVEMBER 22, 2021

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon Plus, the FDA preps you for Thursday with a regulatory soup review. d/b/a Drug Channels Institute.

Specialty Pharmacies 75

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 75

Drug Channels

OCTOBER 27, 2021

Recent posts have covered: Walgreens’ new direction; controversary over independent pharmacy counting; insurer consolidation; retail pharmacy M&A; drug pricing policy; Prime Therapeutics; 340B contract pharmacy litigation; pharmaceutical antitrust; oncology care model; and Peter Bach’s nuptials. d/b/a Drug Channels Institute.

Biosimilars 75

Biosimilars Hospitals Independent Pharmacies Drug Pricing 75

Drug Channels

MARCH 16, 2021

I am pleased to announce our new 2021 Economic Report on U.S. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study: The Latest Trends for U.S. The 2021 Economic Report on U.S. d/b/a Drug Channels Institute.

Drug Pricing 52

Drug Pricing Documentation 52

European Pharmaceutical Review

JANUARY 2, 2024

According to results from a survey by GlobalData, the top challenges for the pharmaceutical industry in 2024 will be inflation, geopolitical conflict and drug pricing pressures. Data outcomes revealed that most respondents from Pharma considered that drug pricing and reimbursement constraints will have a negative impact in 2024.

Drug Pricing 102

Drug Pricing Drug Development 102

RX Note

APRIL 16, 2023

Why Drug Prices Are Rising? Newly developed drugs can be expensive to produce. During patent exclusivity, prices are set higher to offset the high research and development cost (up to billions of dollars). Confidential price discounts prevents everyone from demanding the lowest available price.

Drug Pricing 40

Drug Pricing Documentation Pharmaceutical Companies Pharmaceutical Companies 40

Drug Channels

FEBRUARY 9, 2021

On March 16, 2021, Drug Channels Institute will release The 2021 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. We are providing you with the opportunity to preorder this thoroughly updated and revised 2021 edition at special discounted prices.

Drug Pricing 52

Drug Pricing 52

Drug Channels

NOVEMBER 16, 2021

Below, we offer you a handy table for scoring not only each chain’s participation, but also all changes from 2021 to 2022. One unexpected bright spot has been pharmacies’ participation in the 340B Drug Pricing Program. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Drug Pricing 98

Drug Pricing 98

STAT

OCTOBER 24, 2024

Genetic tests showed that certain patients were predisposed to brain injuries if they took Alzheimer’s drugs in clinical trials, but that information remained secret , The New York Times reports. By 2021, nearly 2,000 volunteers had answered the call to test an experimental Alzheimer’s drug known as BAN2401.

Immunity 261

Immunity Immunization Drug Pricing Drug Development 261

Drug Channels

APRIL 27, 2021

drug pricing policy. Recent posts have covered biosimilars, pharmacist workloads, formularies, pricing, PSAOs, Part D spending, copay accumulators, H.R.3, Recent posts have covered biosimilars, pharmacist workloads, formularies, pricing, PSAOs, Part D spending, copay accumulators, H.R.3, d/b/a Drug Channels Institute.

Specialty Pharmacies 40

Specialty Pharmacies Drug Pricing Biosimilars 40

Big Molecule Watch

APRIL 22, 2024

According to the intervenor complaint , “[f]rom 2012 to 2021, Regeneron’s credit card fee reimbursements for Eylea purchases exceeded $250 million to just one of its several distributors. The post DOJ Files False Claims Act Complaint Against Regeneron, Alleging Fraudulent Eylea Drug Pricing appeared first on Big Molecule Watch.

Drug Pricing 49

Drug Pricing 49